Molecular Diagnostic Market Insights
The worldwide molecular diagnostic market is anticipated to grow at a CAGR of more than 9% from 2017 to 2025. High prevalence of infectious diseases, cancer; increasing awareness & acceptance of personalized medicines, development of biomarkers; & advancements in molecular and genomics technology research are expected to boost growth of the industry.
However, increased cost of molecular diagnostics tools, dearth of skilled labour to handle new & complex platforms, coupled with complex regulatory frameworks are the major factors that are anticipated to hamper industry growth.
Taking this into consideration, expanded cost of molecular diagnostics apparatuses, and lack of skilled labour to deal with new and complex procedures, along with the complicated administrative structure are the central factors expected to restrain industry growth.
Product Type Insights
The molecular diagnostic market is divided into instruments, reagents & kits, services, software and programming. The reagents & kits segment is expected to represent the largest share in the market over the forecast period. The instruments segment is also anticipated to observe high growth rate on account of expanding R&D activities in the biomarker industry.
PCR is anticipated to command the largest share in 2016 and microarray segment is projected to grow at a high CAGR over the coming years. Factors such as the expanding demand for atomic-targeted drugs/treatment (customized medicine) are anticipated to drive the microarray market amid the projected time frame.
Mechanical headways play a vital role in conveying fast and accurate test outcomes. This is evaluated to enable greater penetration of sub-atomic or molecular diagnostics in care (PoC) facilities and healing centres.
The DNA sequencing fragment is expected to witness lucrative development with a CAGR of around 16% from 2017 to 2025. Key factors contributing to the development of DNA sequencing are availability of technologically advanced products with high accuracy, speed, and high throughput screening.
It has been predicted that infectious diseases segment will hold the largest share of the global market in 2016, ensued by the blood screening and oncology segments.
Polymerase Chain Reaction (PCR) is incorporated among specialists, researchers, and social insurance experts to determine variations that underlie hereditary diseases.
Oncology studies utilize MDfor screening, treatment selection, detection, and relapse monitoring of cancer. The current demand for malignancy research treatment in complex molecular tumour diagnostics is very high.
The hereditary examination of samples using next-generation sequencing technologies enables analysts to distinguish hereditary changes and patterns in tumour tissues, thereby helping doctors to determine the most effective options for treatment.
Established laboratory accreditation framework, positive awareness programs for educating patients about early diagnosis, and the rising expenditures of medical services are the main factors fortifying the dominance of the market in North America.
The Asia-Pacific region is expected to develop at the highest CAGR during the projected time frame. The extent of development in this region can be attributed to the existence of high-growth markets such as China, India, and South Korea.
Also, growing external funding for clinical studies in China and India is anticipated to drive developments in the industry.
End - Use Landscape
The end-use landscape entails a list of current and prospective consumers prevailing across the regions. This section provides company addresses, contact details, products, and regional presence of companies who are purchasing or are likely to purchase products from the global molecular diagnostic market over the coming years. The application is mostly used in Hospitals, Laboratories, and Clinics. Some leading purchasers of the market are University of Texas MD Anderson Cancer Centre, Memorial Sloan Kettering Cancer Centre, and Mayo Clinic.
The expanding rate of infectious & fatal diseases, hereditary issues, phenomenal prospects in the field of pharmacogenetics, and the expanding demand for PoC diagnostics is projected to augment sub-atomic diagnostics market growth.
In February 2016, Roche Molecular Diagnostics launched cobas 4800 system which helps in sample preparation using PCR technology for detection and amplification. Already established players are undertaking R&D endeavours to create novel biomarker-based partner diagnostic tests.
F. Hoffmann-La Roche Ltd, Abbott, and bioMérieux SA got the U.S. FDA endorsement for partner diagnostics for cancer therapeutics in 2014. For instance, in the U.S., the introduction of Clinical Laboratory Improvement Amendments certification has prompted utilization rate of PoC devices.
Due to greater and prominent opportunities in both developed and developing nations, organizations are undertaking key initiatives, such as, mergers & acquisitions, new product advancement, and funding ventures to enhance market presence.
Avail customized purchase options to meet your exact research needs: